Mihai CRAIU

Dr. Mihai CRAIU

Carol Davila University of Medicine and Pharmacy, Bucharest, Bucureşti, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Children
Verified
Journal Article
Open access
PDF file
BCBERGHEA ELENA CAMELIA
BERGHEA ELENA CAMELIA
MIMarcela Daniela Ionescu
Marcela Daniela Ionescu
RGRadu Marian Gheorghiu
Radu Marian Gheorghiu
ITIulia Tincu
Iulia Tincu
Cristian CobilinschiCristian Cobilinschi
Cristian Cobilinschi
FBFlorian Berghea
Florian Berghea
Background: Our study aimed to explore the way artificial intelligence (AI) utilization is perceived in pediatric medicine, examining its acceptance among patients (in this case represented by their adult parents), and identify the challenges it presents in order to understand the factors influencing its adoption in clinical settings. Methods: A structured questionnaire was applied to caregivers (parents or grandparents) of children who presented in tertiary pediatric clinics. Results: The most significant differentiations were identified in relation to the level of education (e.g., aversion to AI involvement was 22.2% among those with postgraduate degrees, 43.9% among those with university degrees, and 54.5% among those who only completed high school). The greatest fear among respondents regarding the medical use of AI was related to the possibility of errors occurring (70.1%). Conclusions: The general attitude toward the use of AI can be considered positive, provided that it remains human-supervised, and that the technology used is explained in detail by the physician. However, there were large differences among groups (mainly defined by education level) in the way AI is perceived and accepted.


7 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Victor Daniel MironVictor Daniel Miron
Victor Daniel Miron
ATAndrei Răzvan Toma
Andrei Răzvan Toma
FCFilimon Claudiu
Filimon Claudiu
GBGabriela Bar
Gabriela Bar
MCMihai CRAIU
Mihai CRAIU
Vaccination is one of the most useful medical interventions for controlling certain infectious diseases. The aim of current research is to identify some of the drivers of vaccine hesitancy or acceptance in a rather skeptical European population by addressing parental perception on optional vaccination (OV) perception. Novel tools, delivered by social media, were used in our research attempt. A validated questionnaire was distributed online among parents. Parental knowledge, attitudes and perceptions of OV were analyzed. The majority of parent respondents (55.1%) showed very good knowledge about vaccination and vaccine-preventable diseases, and 76.0% stated that they had given at least one optional vaccine to at least one of their children. The most common optional vaccine administered was the rotavirus vaccine. The level of knowledge appeared to be related to compliance with OV. Concurrently, the rate of vaccine acceptance in the NIP (National Immunization Program) was not correlated with the level of parental knowledge. In total, a high percentage of parents (77.6%) believed that OV can bring an additional health safety benefit to their children. This study shows the need to involve the medical community in a steady dialogue with parents about OV. Raising awareness by presenting clear and understandable information could be a game-changing intervention in mitigating the public health impact of OV-preventable diseases.

1 March 2015 in Vector-Borne and Zoonotic Diseases
Verified
Journal Article
Closed access
YFYariv Fruchtman
Yariv Fruchtman
RSRenana Wilkof Segev
Renana Wilkof Segev
AGAvivit Asher Golan
Avivit Asher Golan
YDYael Dalem
Yael Dalem
MTMuhammad Abu Tailakh
Muhammad Abu Tailakh
ELEugene Leibovitz
Eugene Leibovitz
Data on the various aspects of brucellosis in children living in southern Israel are missing. Our aim was to study the epidemiological, microbiological, diagnostic, clinical, therapeutic and outcome features of brucellosis in children 50% of the children with brucellosis, and B. melitensis was identified in all cases. Arthralgia, weakness, and gastrointestinal complaints were the most common symptoms, and monoarthritis, hepatosplenomegaly, and lymphadenopathy were the most common clinical findings. A considerable number of patients with BB had undetectable/low serum agglutinin titers, suggesting insufficient reliability on serology alone in diagnosis of brucellosis.

13 November 2021 in Medicina
Verified
Journal Article
Open access
PDF file
BCBERGHEA ELENA CAMELIA
BERGHEA ELENA CAMELIA
MCMihai CRAIU
Mihai CRAIU
SASelda Ali
Selda Ali
SCSabina Loredana Corcea
Sabina Loredana Corcea
RBRoxana Silvia Bumbacea
Roxana Silvia Bumbacea
Introduction: The most common clinical manifestation of mango allergy is contact dermatitis, which can be localized or systemic. The sensitising substances that have long been suspected are alk(en)yl catechols and/or alk(en)yl resorcinols. Methods: We reviewed the original articles published on Pubmed, Embase and Cochrane Library before 15 September 2021, on the topic of contact allergy induced by mango and we synthesized the key data. Results: We found 12 case reports and four case series, with a total of 37 patients. Only seven of these cases were reported in patients from mango-cultivating countries, the other 30 were from countries where mango cultivation does not occur, and 26 were also from countries where poison ivy/oak are commonly found. We found that contact dermatitis may occur on the first exposure to mango due to previous sensitisation to urushiol-containing plants. The diagnosis was confirmed by patch testing in some of the cases. There was great heterogeneity between the reagents used. Conclusion: Mango fruit is frequently consumed, but mango induced contact dermatitis, the main hypersensitivity reaction induced by mango, is rare. Further data is necessary for a better understanding of sensitising substances and, consecutively, standardization of patch test reagents.

3 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MRMirela-Elena Ritivoiu
Mirela-Elena Ritivoiu
Cristina Manuela DragoiCristina Manuela Dragoi
Cristina Manuela Dragoi
DMDumitru Matei
Dumitru Matei
ISIustina Stan
Iustina Stan
Alina Crenguţa NicolaeAlina Crenguţa Nicolae
Alina Crenguţa Nicolae
ACAlina Angelica Ciolpan
Alina Angelica Ciolpan
This review presents current updates of pancreatic enzyme replacement therapy in children with cystic fibrosis based on literature published in the last decade and some special considerations regarding pancreatic enzyme replacement therapy in the era of new therapies, such as cystic fibrosis transmembrane conductance regulator modulator therapies. Few articles evaluate the efficacy of pancreatic enzyme replacement therapy in the pediatric population, and most studies also included children and adults with cystic fibrosis. Approximately 85% of cystic fibrosis patients have exocrine pancreatic insufficiency and need pancreatic enzyme replacement therapy. Fecal elastase is the most commonly used diagnostic test for exocrine pancreatic insufficiency, although this value can fluctuate over time. While it is used as a diagnostic test, it cannot be used for monitoring the effectiveness of pancreatic enzyme replacement therapy and for adjusting doses. Pancreatic enzyme replacement therapy, the actual treatment for exocrine pancreatic insufficiency, is essential in children with cystic fibrosis to prevent malabsorption and malnutrition and needs to be urgently initiated. This therapy presents many considerations for physicians, patients, and their families, including types and timing of administration, dose monitoring, and therapy failures. Based on clinical trials, pancreatic enzyme replacement therapy is considered effective and well-tolerated in children with cystic fibrosis. An important key point in cystic fibrosis treatment is the recent hypothesis that cystic fibrosis transmembrane conductance regulator modulators could improve pancreatic function, further studies being essential. Pancreatic enzyme replacement therapy is addressed a complication of the disease (exocrine pancreatic insufficiency), while modulators target the defective cystic fibrosis transmembrane conductance regulator protein. Exocrine pancreatic insufficiency in cystic fibrosis remains an active area of research in this era of cystic fibrosis transmembrane conductance regulator modulator therapies. This new therapy could represent an example of personalized medicine in cystic fibrosis patients, with each class of modulators being addressed to patients with specific genetic mutations.